H1 revenues show continued double-digit core growth, with further contract mobilisations and a strong pipeline underpinning FY expectations. The group is not immune from inflationary pressures however and management has elected to prioritise market share growth over near term margin protection. We update our forecasts accordingly, now expecting an EBITDA loss for this year of £1.3m. Management has additional levers to control discretionary expenditure and working capital management such that it ....

03 Nov 2022
H1 Trading update

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
H1 Trading update
Yourgene Health Plc (YGEN:LON) | 0.2 0 0.0% | Mkt Cap: 6.67m
- Published:
03 Nov 2022 -
Author:
Chris Glasper -
Pages:
3 -
H1 revenues show continued double-digit core growth, with further contract mobilisations and a strong pipeline underpinning FY expectations. The group is not immune from inflationary pressures however and management has elected to prioritise market share growth over near term margin protection. We update our forecasts accordingly, now expecting an EBITDA loss for this year of £1.3m. Management has additional levers to control discretionary expenditure and working capital management such that it ....